OTTAWA – A class-action lawsuit against pharmaceutical giant Pfizer Canada over its anti-smoking drug Champix will proceed, an Ontario Superior Court has ruled.
The Ontario court certified the class-action lawsuit in June 2012, but Pfizer sought leave to appeal the certification order.
Get weekly health news
On Friday, lawyers for the plaintiffs, including Toronto-based firm McPhadden Samac Tuovi LLP, announced a judge has dismissed Pfizer’s appeal.
The plaintiffs allege the drug maker failed to warn Canadians taking the drug that they could suffer psychiatric side effects such as depression, anxiety and suicidal thoughts.
- Marigold fined $120K for injury on Valley Line West LRT construction site in 2023
- Premier Moe says new trade deal with India would benefit Saskatchewan despite tariffs
- Supreme Court will hear case about closed Acadian Peninsula courthouses
- Stolen SUV traced to West Africa results in fraud, theft charges
The allegations have not been proven in court.
Pfizer says there is no reliable scientific evidence proving that Champix causes these adverse reactions.
Comments
Want to discuss? Please read our Commenting Policy first.